Market News CYPT CALYPTE BIOMEDICAL CORPORATION
OTC Journal Reports on CYPT
THURSDAY , JANUARY 08, 2004 10:46 AM
A recent OTC Journal alert noted the following about Calypte Biomedical Corporation (OTCBB: CYPT):
"CYPT got a legitimate $10 million financing, turned off the stock certificate printing press, and the stock rocketed ten fold. This is the only company in the world with a FDA approved urine test for the HIV Virus."
CYPT is a health care company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Imnunodeficiency Virus Type 1, sexually transmitted diseases and other chronic illnesses.
CYPT has a current price of $0.49900 per share.
The OTCjournal.com Newsletter is owned by MarketByte, LLC.
According to the OTC Journal disclaimer, MarketByte LLC has been compensated a fee of 250,000 free trading shares of Calypte common stock by First Stage Capital for coverage of Calypte Biomed. On August 12, 2002, MarketByte LLC entered into an agreement directly with Calypte Biomed to continue coverage of the company through October 31, 2002. Calypte Biomed compensated $25,000 cash as compensation, and an additional 300,000 shares of free trading stock were compensated by a third party on behalf of the company. On November 1, 2002, MarketByte LLC and Calypte Biomed to agreed to renew the agreement to extend through January 31, 2003 in return for $25,000 in cash, and an additional 300,000 shares of free trading stock were compensated by a third party.
Copyright © 2002. The Nasdaq Stock Market, Inc
Copyright ©2002 Knobias.com, LLC
Die Börse scheint es aber eine Husten zu interessieren.
Grüße, ZN |